Diagnostic value of IP-10 in rheumatoid arthritis: a systematic review and Meta-analysis

LI Qing-ru; FANG Xin-yu; XIA Yuan-rui; GUO Heng-sheng; WANG Jun-ping; MAO Yan-mei; SHUAI Zong-wen; YE Dong-qing

doi:10.16462/j.cnki.zhjbkz.2021.08.012

Volume 25 Issue 8

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(8): 935-942

LI Qing-ru, FANG Xin-yu, XIA Yuan-rui, GUO Heng-sheng, WANG Jun-ping, MAO Yan-mei, SHUAI Zong-wen, YE Dong-qing. Diagnostic value of IP-10 in rheumatoid arthritis: a systematic review and Meta-analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(8): 935-942. doi: 10.16462/j.cnki.zhjbkz.2021.08.012

Citation:

LI Qing-ru, FANG Xin-yu, XIA Yuan-rui, GUO Heng-sheng, WANG Jun-ping, MAO Yan-mei, SHUAI Zong-wen, YE Dong-qing. Diagnostic value of IP-10 in rheumatoid arthritis: a systematic review and Meta-analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(8): 935-942. doi: 10.16462/j.cnki.zhjbkz.2021.08.012

Citation:

LI Qing-ru, FANG Xin-yu, XIA Yuan-rui, GUO Heng-sheng, WANG Jun-ping, MAO Yan-mei, SHUAI Zong-wen, YE Dong-qing. Diagnostic value of IP-10 in rheumatoid arthritis: a systematic review and Meta-analysis[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(8): 935-942. doi: 10.16462/j.cnki.zhjbkz.2021.08.012

PDF( 6558 KB)

Diagnostic value of IP-10 in rheumatoid arthritis: a systematic review and Meta-analysis

doi: 10.16462/j.cnki.zhjbkz.2021.08.012

1.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei 230032, China
2.
Department of Rheumatology and Immunology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Funds:

National Natural Science Foundation of China 81872693

More Information

Corresponding author: SHUAI Zong-wen, E-mail: amushuaizw@163.com; YE Dong-qing, E-mail: anhuiydq@126.com
Received Date: 2021-04-09
Rev Recd Date: 2021-06-07

Available Online: 2021-08-24

Publish Date: 2021-08-10

Abstract

Abstract

Objective We aimed to analyze the changes of interferon-inducible protein 10 (IP-10) in rheumatoid arthritis (RA) and evaluate the diagnostic value of IP-10 in RA and its correlation with disease activity. Methods We collected articles related to our research topic through an electronic literature search from the Cochrane Library, Scopus, and Pubmed (up to Sep16th, 2020). Quality assessment of diagnostic accuracy studies (QUADAS-2) tool was used to assess the quality of collected articles, and quantitative and comprehensive analysis was conducted. Results 17 studies were finally included in this study. IP-10 level in RA patients was higher than health controls [pooled standard mean difference (SMD) = 0.93, 95% CI= 0.51-1.35]. Besides, IP-10 levels in RA patients differed from osteoarthritis (OA) controls, with a pooled SMD and 95% CI being 3.84 (0.76-6.92). We found no significant difference in IP-10 levels between RA patients and systemic lupus erythematosus (SLE) controls. The pooled diagnostic odds ratio (DOR) value for IP-10 to diagnose RA was 65.70 (1.52-2 844.43) and AUC value was 0.899 6. Conclusion IP-10 levels differ from RA patients to HC and OA controls, it may be a potential diagnostic biomarker.
- Interferon-inducible protein 10,
- Rheumatoid arthritis,
- Biomaker,
- Osteoarthritis,
- Systemic lupus erythematosus,
- Systematic review,
- Meta-analysis

FullText(HTML)

References(36)

References

[1]	Lloyd S, Bujkiewicz S, Wailoo AJ, et al. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and Meta-analysis[J]. Rheumatology (Oxford), 2010, 49: 2313-2321. DOI: 10.1093/rheumatology/keq169.
[2]	Luster AD. Chemokines--chemotactic cytokines that mediate inflammation[J]. Engl J Med, 1998, 338(7): 436-445. DOI: 10.1056/NEJM199802123380706.
[3]	Allen SJ, Crown SE. Chemokine: receptor structure, interactions, and antagonism[J]. Annu Rev Immunol, 2007, 25: 787-820. DOI: 10.1146/annurev.immunol.24.021605.090529.
[4]	Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation[J]. N Engl J Med, 2006, 354(6): 610-621. DOI: 10.1056/NEJMra052723.
[5]	Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity[J]. Cytokine, 2018, 109: 24-28. DOI: 10.1016/j.cyto.2018.02.012.
[6]	Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils[J]. J Immunol, 1999, 162(8): 4928-4937. http://www.ncbi.nlm.nih.gov/pubmed/10202039
[7]	Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529-536. DOI: 10.7326/0003-4819-155-8-201110180-00009.
[8]	Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in Meta analyses[J]. BMJ, 2003, 327(7414): 557-560. DOI: 10.1136/bmj.327.7414.557.
[9]	Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy[J]. Ann Intern Med, 2008, 149(12): 889-897. DOI: 10.7326/0003-4819-149-12-200812160-00008.
[10]	Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus[J]. Cytokine, 2000, 12(10): 1561-1565. DOI: 10.1006/cyto.2000.0757.
[11]	Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 Ligands in Rheumatoid Arthritis Synovium[J]. Clin Immunol, 2001, 98: 39-45. DOI: 10.1006/clim.2000.4957.
[12]	Nishioji K, Okanoue T, Itoh Y, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes[J]. Clin Exp Immunol, 2001, 123(2): 271-279. DOI: 10.1046/j.1365-2249.2001.01391.x.
[13]	Hanaoka R, Kasama T, Muramatsu M, et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis[J]. Arthritis Res Ther, 2003, 5(2): R74-81. DOI: 10.1186/ar616.
[14]	Ueno A, Yamamura M, Iwahashi M, et al. The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis[J]. Rheumatol Int, 2005, 25: 361-367. DOI: 10.1007/s00296-004-0449-x.
[15]	Deane KD, O'Donnell CI, Hueber W, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner[J]. Arthritis Rheum, 2010, 62(11): 3161-3172. DOI: 10.1002/art.27638.
[16]	Kuan WP, Tam LS, Wong CK, et al. CXCL 9 and CXCL 10 as Sensitive markers of disease activity in patients with rheumatoid arthritis[J]. J Rheumatol, 2010, 37(2): 257-264. DOI: 10.3899/jrheum.090769.
[17]	Kåss AS, Lea TE, Torjesen PA, et al. The association of luteinizing hormone and follicle-stimulating hormone with cytokines and markers of disease activity in rheumatoid arthritis: a case-control study[J]. Scand J Rheumatol, 2010, 39: 109-117. DOI: 10.3109/03009740903270607.
[18]	Shah D, Wanchu A, Bhatnagar A. Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis[J]. Immunobiology, 2011, 216(9): 1010-1017. DOI: 10.1016/j.imbio.2011.04.001.
[19]	Sato M, Ohtsuka K, Takahashi R, et al. Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis[J]. Open Access Rheumatol, 2011, 3: 1-7. DOI: 10.2147/OARRR.S16210.
[20]	Eriksson C, Rantapää-Dahlqvist S, Sundqvist KG, et al. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis[J]. Scand J Rheumatol, 2013, 42: 260-265. DOI: 10.3109/03009742.2012.754937.
[21]	Hampel U, Sesselmann S, Iserovich P, et al. Chemokine and cytokine levels in osteoarthritis and rheumatoid arthritis synovial fluid[J]. J Immunol Methods, 2013, 396(1-2): 134-139. DOI: 10.1016/j.jim.2013.08.007.
[22]	Dhir V, Sandhu A, Gupta N, et al. Change in CXCL10 on treatment with methotrexate similar to that reported with infliximab: comments on the article by Eriksson et al[J]. Scand J Rheumatol, 2014, 43(1): 83-84. DOI: 10.3109/03009742.2013.813961.
[23]	Rodríguez-Carrio J, Alperi-López M, López P, et al. High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: a potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein[J]. J Clin Lipidol, 2017, (11)4: 1043-1054. DOI: 10.1016/j.jacl.2017.05.009.
[24]	Rico MC, Manns JM, Driban JB, et al. Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis[J]. Transl Res, 2008, 152(2): 95-98. DOI: 10.1016/j.trsl.2008.06.002.
[25]	Imam AM, Hamed AM, Nasef SI, et al. Biochemical analysis of C-X-C motif chemokine ligand 10 (CXCL10) as a biomarker in patients with rheumatoid arthritis[J]. Egypt J Immunol, 2019, 26(2): 79-86.
[26]	Muhsin HY, Kadri ZHM, Ad'hiah AH, et al. Predictive significance of CXCL8, CXCL10 and CXCL16 in juvenile idiopathic and rheumatoid arthritis Iraqi patients[J]. Egyptian Rheumatologist, 2019. DOI: 10.1016/j.ejr.2019.06.002.
[27]	Puapatanakul P, Chansritrakul S, Susantitaphong P, et al. Interferon-inducible protein 10 and disease activity in systemic lupus erythematosus and lupus nephritis: a systematic review and Meta-analysis[J]. Int J Mol Sci, 2019, 20(19): 4954. DOI: 10.3390/ijms20194954.
[28]	Pandya JM, Lundell AC, Andersson K, et al. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker[J]. Arthritis Res Ther, 2017, 19(1): 20. DOI: 10.1186/s13075-017-1224-1.
[29]	Chen DY, Shen GH, Chen YM, et al. Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis[J]. Int J Tuberc Lung Dis, 2011, 15(2): 192-200. http://www.ncbi.nlm.nih.gov/pubmed/21219680
[30]	Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population[J]. J Rheumatol, 2008, 35(5): 776-781. DOI: 10.1016/j.jbspin.2007.10.004.
[31]	Laragione T. Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix Metalloproteinase 2 activation, interleukin-6 and CXCL10[J]. Mol Med, 2012, 18: 1009-1017. DOI: 10.2119/molmed.2012.00173.
[32]	Kasama T, Isojima S, Umemura M, et al. Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis[J]. Rheumatol Int, 2014, 34(3): 429-433. DOI: 10.1007/s00296-013-2778-0.
[33]	Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study[J]. Arthritis Res Ther, 2016, 18: 93. DOI: 10.1186/s13075-016-0995-0.
[34]	Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4[J]. J Exp Med, 2003, 197: 1537-1549. DOI: 10.1084/jem.20021897.
[35]	Muntyanu A, Abji F, Liang K, et al. Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis[J]. Arthritis Res Ther, 2016, 18(1): 296. DOI: 10.1186/s13075-016-1196-6.
[36]	Laragione T, Brenner M, Sherry B, et al. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis[J]. Arthritis Rheum, 2011, 63(11): 3274-3283. DOI: 10.1002/art.30573.